Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?

Abstract Recently, calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other co...

Full description

Saved in:
Bibliographic Details
Main Authors: Keisuke Suzuki (Author), Shiho Suzuki (Author), Hiroaki Fujita (Author), Hirotaka Sakuramoto (Author), Mukuto Shioda (Author), Koichi Hirata (Author)
Format: Book
Published: Wiley, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a98f1b257c6d40e4abf51f59df39d7d0
042 |a dc 
100 1 0 |a Keisuke Suzuki  |e author 
700 1 0 |a Shiho Suzuki  |e author 
700 1 0 |a Hiroaki Fujita  |e author 
700 1 0 |a Hirotaka Sakuramoto  |e author 
700 1 0 |a Mukuto Shioda  |e author 
700 1 0 |a Koichi Hirata  |e author 
245 0 0 |a Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine? 
260 |b Wiley,   |c 2024-06-01T00:00:00Z. 
500 |a 2574-173X 
500 |a 10.1002/npr2.12444 
520 |a Abstract Recently, calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other comorbidities, such as psychiatric complications in patients with migraine. However, there are no reports examining the effect of CGRP mAbs on dystonia. We treated a patient with comorbid migraine and focal task‐specific dystonia (writer's cramp) with a CGRP mAb (erenumab) because of an increase in monthly migraine days despite the addition of migraine prophylaxis. In this patient, erenumab treatment for 3 months led to improvements in symptoms of both focal dystonia and migraine, suggesting a role for CGRP in the pathophysiology of both conditions. 
546 |a EN 
690 |a calcitonin gene‐related peptide 
690 |a focal task‐specific dystonia 
690 |a migraine 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
655 7 |a article  |2 local 
786 0 |n Neuropsychopharmacology Reports, Vol 44, Iss 2, Pp 482-484 (2024) 
787 0 |n https://doi.org/10.1002/npr2.12444 
787 0 |n https://doaj.org/toc/2574-173X 
856 4 1 |u https://doaj.org/article/a98f1b257c6d40e4abf51f59df39d7d0  |z Connect to this object online.